ARS Pharmaceuticals Inc [SPRY] stock is trading at $13.33, down -1.55%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The SPRY shares have gain 22.52% over the last week, with a monthly amount glided 27.62%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
ARS Pharmaceuticals Inc [NASDAQ: SPRY] stock has seen the most recent analyst activity on August 13, 2024, when Raymond James upgraded its rating to a Strong Buy and also boosted its price target to $22 from $18. Previously, Leerink Partners reaffirmed its Outperform rating on August 12, 2024, and elevated its price target to $20. On July 25, 2024, Raymond James initiated with a Outperform rating and assigned a price target of $18 on the stock. Leerink Partners upgraded its rating to a Outperform and increased its price target to $18 on March 05, 2024. William Blair upgraded its rating to a Outperform. William Blair downgraded its rating to Mkt Perform for this stock on September 20, 2023. In a note dated January 31, 2023, Wedbush initiated an Outperform rating and provided a target price of $10 on this stock.
ARS Pharmaceuticals Inc [SPRY] stock has fluctuated between $2.55 and $13.69 over the past year. Currently, Wall Street analysts expect the stock to reach $20 within the next 12 months. ARS Pharmaceuticals Inc [NASDAQ: SPRY] shares were valued at $13.33 at the most recent close of the market. An investor can expect a potential return of 50.04% based on the average SPRY price forecast.
Analyzing the SPRY fundamentals
ARS Pharmaceuticals Inc [NASDAQ:SPRY] reported sales of 0.50M for the trailing twelve months, which represents a growth of 4900.00%. Gross Profit Margin for this corporation currently stands at 0.87% with Operating Profit Margin at -120.71%, Pretax Profit Margin comes in at -95.37%, and Net Profit Margin reading is -95.37%. To continue investigating profitability, this company’s Return on Assets is posted at -0.2, Equity is -0.2 and Total Capital is -0.26. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 13.16 points at the first support level, and at 12.99 for the second support level. However, for the 1st resistance point, the stock is sitting at 13.61, and for the 2nd resistance point, it is at 13.89.
Ratios To Look Out For
For context, ARS Pharmaceuticals Inc’s Current Ratio is 32.78. Further, the Quick Ratio stands at 32.78, while the Cash Ratio is 5.45. Considering the valuation of this stock, the price to sales ratio is 2584.42, the price to book ratio is 6.00.
Transactions by insiders
Recent insider trading involved Dorsey Brian, Chief Operating Officer, that happened on Aug 13 ’24 when 30000.0 shares were sold. CHIEF MEDICAL OFFICER, Tanimoto Sarina completed a deal on Aug 13 ’24 to sell 100000.0 shares. Meanwhile, PRESIDENT AND CEO Lowenthal Richard E sold 100000.0 shares on Aug 13 ’24.
